18 August 2020Insurance

CFC expands life science offering to mid-market sector

Specialist insurance provider CFC has expanded its life sciences insurance offering to the mid-market sector on a global basis.

The company will now offer excess products liability, E&O and clinical trials solutions for global clinical research organisations and companies manufacturing or selling medical devices, functional food and dietary supplements with a revenue threshold of £2.5 billion.

CFC first entered the life science market in 2009 and currently services over 4,000 life science businesses in over 25 countries around the world.

“The life science sector is possibly one of the most dynamic and has expanded faster than most other industries in recent years, fuelled by increasing patient and consumer demand for high-quality products and treatments,” said Sean Burke, CFC’s life science team leader. “While it hasn’t escaped the impact of the global pandemic, it is an industry sector that could make tremendous future contributions to economies around the world as it continues to pioneer treatments for new and existing conditions.”

He added: “Our team has over a decade’s experience of providing bespoke insurance products for the complex risks these businesses face, and so extending our appetite to now be able to deliver solutions for mid-market companies is a natural evolution of our offering.”

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Insurance
22 December 2025   Brokerage complaints spin tawdry tales to frame defections as low-rent theft & espionage.
Insurance
19 December 2025   If profits slip too far, insurers may cut coverage, hike premiums, squeezing affordability.
Insurance
19 December 2025   Appointment comes at pivotal time as geopolitical tensions drive demand.